Is It Too Late to Start Immunotherapy — The Honest Answer at Stage 4

Sometimes, yes — and being told so is honest care, not abandonment. Stage 4 on its own does not make it too late. What usually decides is how well the person is functioning. Someone up and about may be a candidate. Someone who has become bed-bound over a few weeks generally is not.

Families often reach this question late — sometimes from an inpatient bed, sometimes after a scan showing progression on everything tried so far. Being offered immunotherapy is not by itself evidence that it will help. The treatment takes weeks to show any effect on a scan, needs a reasonably intact immune system to work through, and carries immune-related side effects that a fragile patient tolerates poorly. A team willing to tell you plainly that this is not the right moment is giving you better information than a team that starts a cycle to avoid a hard conversation.

This page is about the decision to start. If treatment is already running and no longer controlling the disease, that is a different conversation — the related reading at the end of this page covers it.

ECOG is a standard clinical scale, not a CION rating. Ask which score has been recorded and why — it is a number you are entitled to know, and it explains most of what follows. It is not the only input: organ function, prior treatment, biomarker status and the patient’s own wishes all count.

It is a possibility, not a promise. Immunotherapy helps in a proportion of patients and does nothing for the rest. No test tells you in advance which group a person is in. Response, when it comes, usually takes weeks to appear on a scan — which is exactly what a rapidly declining patient may not have.

Biomarker results shift the odds without settling them. PD-L1 expression, MSI-high or mismatch-repair-deficient status and tumour mutational burden all inform the decision, and NCCN, ASCO and ESMO publish response-rate ranges by cancer type and biomarker status. Ask for the range that applies to this specific report — not a general figure read online, and not a number quoted without a source.

Then ask two follow-ups. When would the first assessment scan happen, and what is the plan if it shows no response? A treatment offered without a stopping rule is not yet a plan. Cost belongs in the same conversation: this is repeat day-care cycles over months, so ask for the figure in writing and treat any number you are given as indicative, as of August 2026.

None of these is an absolute rule for every patient. Each is a reason to hold a goals-of-care conversation rather than proceed by default — and to have that conversation with the patient in the room wherever they are well enough to take part.

Care continues — it changes shape. The focus moves to controlling pain, breathlessness, appetite and sleep, and to supporting the family. That is best supportive and palliative care. It is a parallel service that can run alongside treatment or in place of it, not a last resort.

Deciding against a treatment that is unlikely to help, and likely to add side effects and hospital visits to the time that remains, is an active clinical decision. It is not the absence of care, and it is not giving up. In practice it usually means more time at home, fewer infusion visits, and a care plan built around what the patient says matters most.

At CION, immunotherapy itself is delivered as day care at our centres, and response-assessment PET-CT is coordinated at partner imaging centres rather than performed in-house. Supportive care planning — symptom control, nutrition input, psycho-oncology support for patient and family — sits alongside both paths, and a referral commits you to nothing. The decision is rarely final on day one either: if symptoms settle and function improves, the question can be reopened. Ask for a review date rather than a yes-or-no answer on the spot.

• If the worry is that declining treatment means being left with nothing, Palliative Care Alongside Immunotherapy, Not Instead of It explains what symptom-focused care actually involves and why it can start today.
• If treatment has already begun and the question is whether to continue, Stopping Treatment: How Families Reach the Decision walks through that conversation rather than this one.
• If cost is the pressure behind the question and not the clinical picture, When the Money Runs Out Before the Treatment Does covers the options families are rarely told about.
• For the full picture of how immunotherapy is assessed, delivered and monitored at CION, see our immunotherapy hub.

Facing this decision now? Get a free second opinion and a medical oncologist will go through the performance status, the realistic timeline and the alternative with you — in plain language, whichever way you are leaning.